8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A detailed analysis of the methodological limitations, enrollment biases, and generalizability gaps in the Konopka 2019 trial showing metformin blunts exercise adaptations in older adults.
A methodology deep-dive into the Konopka 2019 RCT examining how metformin blunts aerobic exercise adaptations in older adults, covering randomization, blinding, endpoint selection, and statistical approach.
Health-economic analysis of the Konopka 2019 trial showing metformin blunts aerobic exercise adaptations in older adults, with implications for cost per QALY, payer coverage, and individual value calculations.
Analysis of follow-up data and long-term implications from the Konopka 2019 trial showing metformin blunted aerobic exercise adaptations in older adults without diabetes.
Full breakdown of the Konopka 2019 trial results showing metformin blunts aerobic exercise adaptations in older adults, including effect sizes, mitochondrial respiration data, and subgroup response patterns.
Detailed subgroup analysis of the Konopka 2019 RCT examining how age, sex, BMI, and baseline fitness modulated metformin's blunting effect on aerobic exercise adaptations in older adults.
A plain-English deep dive into the Konopka 2019 trial showing metformin blunts aerobic exercise adaptations in older adults without diabetes, covering methodology, results, and clinical implications.
A clinical-practice analysis of the Konopka 2019 trial showing metformin blunts aerobic exercise adaptations in older adults, with implications for longevity prescribing in non-diabetic populations.